Navigation Links
Sanofi Pasteur Receives Additional Order from U.S. Government to Produce Influenza A (H1N1) Vaccine
Date:9/21/2009

LYON, France and SWIFTWATER, Pa., Sept. 21 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the company has received an additional order from the U.S. Department of Health and Human Services (HHS) to produce vaccine to help protect against the Influenza A (H1N1) 2009 virus. The new order is for the production of bulk antigen equivalent to 27.3 million doses based on 15 mcg of antigen per dose. Specifications for formulation and filling of this new bulk order will be the subject of a separate order. To date, Sanofi Pasteur has committed to the U.S. government a total of 75.3 million doses of Influenza A (H1N1) 2009 Monovalent Vaccine.

"We are pleased to be able to support the U.S. government's pandemic response efforts through the production of additional doses of A (H1N1) vaccine," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. "As the only company manufacturing inactivated influenza vaccine in the U.S., we recognize the important role Sanofi Pasteur serves in the country's pandemic response plan and we have committed our resources to responding to our public health needs."

Sanofi Pasteur began commercial production of the new influenza vaccine in June using the novel virus strain to provide doses for clinical trials and to respond to the initial order from HHS. Influenza A (H1N1) 2009 Monovalent Vaccine was licensed by the U.S. Food and Drug Administration on September 15. Sanofi Pasteur is testing the immunogenicity and safety of the Influenza A (H1N1) 2009 Monovalent Vaccine produced in the U.S. through clinical trials, which began in the U.S. on August 6. Final data from these clinical trials will provide additional information to guide recommendations on the optimal dosage, number of doses and schedule.

Sanofi Pasteur operates influenza vaccine production facilities in the U.S. and in France. Production of the new A (H1N1) vaccine for HHS is being performed at the company's U.S.-based production facility.

About Influenza A (H1N1) 2009 Monovalent Vaccine

The U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine is an inactivated influenza virus vaccine indicated for active immunization of persons six months of age and older against influenza disease caused by pandemic (H1N1) 2009 virus.

The Influenza A (H1N1) 2009 Monovalent Vaccine is manufactured by the same process as Sanofi Pasteur's seasonal trivalent influenza virus vaccine licensed in the U.S. Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009 (H1N1) v-like virus. Influenza A (H1N1) 2009 Monovalent Vaccine is licensed for single-dose presentations in syringes and vials and in multi-dose vials. There is no preservative used in the singledose presentations. Multi-dose vials contain a preservative.

Safety Information for Influenza A (H1N1) 2009 Monovalent Vaccine

Influenza vaccine should not be administered to anyone with a known severe hypersensitivity to egg

proteins, any vaccine component or life-threatening reactions after previous administration of any

influenza vaccine. Recurrence of Guillain-Barre syndrome (GBS) has been temporally associated with the administration of influenza vaccine. The decision to give Influenza A (H1N1) 2009 Monovalent Vaccine to individuals who have a prior history of GBS should be based on careful consideration of the potential benefits and risks. Vaccination with Influenza A (H1N1) 2009 Monovalent Vaccine may not protect all individuals.

Before administering Influenza A (H1N1) 2009 Monovalent Vaccine, please see full U.S. Prescribing Information at www.vaccineplace.com/products.

About Influenza Vaccine Production at Sanofi Pasteur

Sanofi Pasteur operates influenza vaccine production facilities in Val de Reuil, France and in Swiftwater, Pa. (U.S.). All Sanofi Pasteur influenza vaccine facilities have been designed and built to be able to switch from seasonal influenza vaccine production to pandemic influenza vaccine production.

Sanofi Pasteur produces approximately 40 percent of the influenza vaccines distributed worldwide and more than 45 percent of the influenza vaccines distributed in the U.S. for the 2008-2009 influenza season. More information about Sanofi Pasteur's pandemic preparedness efforts can be found at www.pandemic.influenza.com.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2008, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us.

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    Contacts
    Global Media Relations               US Media Relations
    Pascal Barollier                     Donna Cary
    T. +33-(0)4-37-37-50-38              T. +1-570-957-0717
    pascal.barollier@sanofipasteur.com   donna.cary@sanofipasteur.com
    www.sanofipasteur.com                www.sanofipasteur.us


'/>"/>
SOURCE Sanofi Pasteur
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. FDA Licenses Sanofi Pasteurs Pandemic Influenza Vaccine
2. Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer
3. Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza
4. Beacon Equity Researches: Sanofi-Aventis, Amazon, Yahoo, Johnson & Johnson, Novavax and NexMed
5. Sanofi Pasteur Receives Order from U.S. Government to Produce New Influenza A(H1N1) Vaccine
6. U.S. FDA Licenses Sanofi Pasteurs New Influenza Vaccine Manufacturing Facility
7. Sanofi-aventis Announces Good First-quarter 2009 Performance
8. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
9. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
10. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
11. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 03, 2016 , ... In April, Amerec launched a new website designed with ... the best steam and sauna solutions. , First, the Amerec website has been redesigned ... all of the site’s features, especially the Steam Builder Tool , to both ...
(Date:5/3/2016)... ... 2016 , ... California health startup Pegara announced today the ... assess their risk of developing Alzheimer’s disease. Using a questionnaire based on years ... Score™” that summarizes how their lifestyle choices may affect their chances of developing ...
(Date:5/3/2016)... ... May 03, 2016 , ... Horizon Blue Cross Blue ... as one of the nation’s most accomplished business technology innovators by InformationWeek, earning ... recognition for technology achievements that have enabled the delivery of the company’s innovative ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the car or cowering ... "Pet owners often think anxiety only manifests itself as trembling or ‘tail between the ... there’s things that be done about it,” says Dr. Jim Lowe, technical services veterinarian ...
(Date:5/3/2016)... ... May 03, 2016 , ... Nationally recognized personal injury law firm Monge & Associates ... roses to anyone who wants one for their Mother or any other mother figure. , ... contributions of Mothers.” Monge goes on to say, “we are choosing to do this ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/2/2016)... , May 2, 2016  Deerfield announced today ... of Graybug Vision, Inc. Graybug Vision is an ... that may transform care for ocular diseases including ... Vision,s technology was first developed at Johns Hopkins ... startup venture. Graybug Vision is ...
(Date:4/29/2016)... , April 29, 2016  In the next ... to shift from systems dependent on CRTs monitors to ... of modality CRT Medical monitors and will automatically ... a host of foreseeable benefits to this technological ... existing modalities have to be replaced in order ...
Breaking Medicine Technology: